News from rigel pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 13, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary...

Aug 05, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Second Quarter 2014 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014. For the...

Jul 16, 2014, 08:35 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Initiates Phase 3 Studies of Fostamatinib in ITP

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib,...

May 29, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at Jefferies 2014 Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to...

May 07, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces First Quarter 2014 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2014. For the first...

Apr 30, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Webcast of Investor Day on May 6, 2014

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host an Investor Day on Tuesday, May 6, 2014 from 9:30 a.m. to 12:00...

Mar 06, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Publication of R118 AMPK Activator Research

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with its...

Mar 04, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Fourth Quarter and Year End 2013 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013. For the...

Feb 27, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Participation at Two Investor Conferences

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details of...

Feb 06, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Participation at Two Investor Conferences

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is...

Jan 10, 2014, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present...

Dec 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at Oppenheimer Healthcare Conference

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operations officer, is...

Nov 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Third Quarter 2013 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30,...

Oct 24, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Provides Pipeline Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological...

Sep 06, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel to Present at Stifel Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to...

Sep 05, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel To Focus On ITP, DLE And Dry Eye

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced its plans to focus the Company's resources on the completion of three lead...

Aug 26, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel's R343 Did Not Meet Primary Endpoint in Asthma Study

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for...

Aug 06, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Announces Second Quarter 2013 Financial Results

 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30,...

Jun 04, 2013, 02:00 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel Will Resume Responsibility for Fostamatinib Program

 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the...

May 22, 2013, 07:30 ET
Rigel Pharmaceuticals, Inc.  (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a...